Stroke News and Research

RSS

A stroke is a medical emergency. Strokes happen when blood flow to your brain stops. Within minutes, brain cells begin to die. There are two kinds of stroke. The more common kind, called ischemic stroke, is caused by a blood clot that blocks or plugs a blood vessel in the brain. The other kind, called hemorrhagic stroke, is caused by a blood vessel that breaks and bleeds into the brain. "Mini-strokes" or transient ischemic attacks (TIAs), occur when the blood supply to the brain is briefly interrupted.

Bristol-Myers Squibb reports strong sales and earnings growth for third quarter 2009

Bristol-Myers Squibb Company today reported strong sales and earnings growth for the third quarter 2009.

22 Oct 2009

PacificGMP selected by ArmaGen Technologies to produce its proprietary protein for a Phase 1 clinical trial

PacificGMP, the leader in single-use bioprocessing for development and manufacturing for its client partners, announced that ArmaGen Technologies has selected it to produce its proprietary protein for a Phase 1 clinical trial.

22 Oct 2009

Peripheral arterial disease linked to lifestyle changes

Modifying the risk of peripheral arterial disease (or PAD)-with healthy lifestyle changes-remains vital to one's health, note researchers in a recent issue of the Journal of Vascular and Interventional Radiology. And while PAD can progress and worsen over time, there is not enough evidence yet to advocate minimally invasive treatment in patients who have had a narrowing or blockage of a leg artery but showing no signs or symptoms of the disease, say Irish researchers in a retrospective study of more than 900 individuals.

22 Oct 2009

People in developing countries spend 90% of all medical expenditures for diabetes care

Type 2 diabetes is often seen as a condition affecting older, unproductive adults in wealthy countries. However, the reality is that 70% of people with diabetes now live in low and middle-income countries and the economic impact of diabetes is much greater in poorer countries.

22 Oct 2009

New research suggests physical therapy helps restore variety of functions after neurological injury

New research suggests a tailored approach to physical therapy after a neurological injury such as a stroke, traumatic brain injury or spinal cord injury could help restore a wider variety of functions.

22 Oct 2009

New study suggests potential treatment for blindsight patients

Although we assume we can see everything in our field of vision, the brain actually picks and chooses the stimuli that come into our consciousness. A new study in the Association for Research in Vision and Ophthalmology's Journal of Vision reveals that our brains can be trained to consciously see stimuli that would normally be invisible.

22 Oct 2009

iPierian to participate in $3.7 million NIH grant awarded to The Johns Hopkins University

iPierian, Inc., a biopharmaceutical company focused on changing the paradigm of drug discovery and development through the application of cellular reprogramming, today announced that it has been selected to participate in a $3.7 million National Institutes of Health (NIH) Grand Opportunities (GO) grant awarded to The Johns Hopkins University.

22 Oct 2009

Shire to file a Biologics License Application for REPLAGAL with the FDA

Shire plc, the global specialty biopharmaceutical company, announces plans to file a Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA) for REPLAGAL(R) (agalsidase alfa), its enzyme replacement therapy for Fabry disease, by the end of the year.

21 Oct 2009

Oxygen Biotherapeutics announces its expanded product development plan

Oxygen Biotherapeutics, Inc. announced its expanded product development plan.

21 Oct 2009

APP Pharmaceuticals to launch Chlorothiazide Sodium for Injection

APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc., announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to market Chlorothiazide Sodium for Injection, USP. APP expects to launch Chlorothiazide Sodium for Injection, USP in the fourth quarter of 2009.

21 Oct 2009

Comparative Effectiveness Research: One way to beat the competition

A higher percentage of companies are using Comparative Effectiveness Research to help with pricing and reimbursement decisions, according to new research from Cutting Edge Information.

21 Oct 2009

Class action lawsuit by patients who received high dosage of radiation during their CT brain perfusion scans

A class action lawsuit (Case #BC4241898) was just filed in Los Angeles Superior Court against Cedars Sinai Medical Center, GE Healthcare, Inc., and GE Healthcare Technologies on behalf of patients who received 8-times the approved dosage of radiation during their CT brain perfusion scans to diagnose strokes.

21 Oct 2009

Findings suggest a new approach to the rehabilitation of stroke patients

What's new: Researchers at MIT and San Camillo Hospital in Venice, Italy, have shown that motor impairments in stroke patients can be understood as impairments in specific combinations of muscle activity, known as synergies.

21 Oct 2009

MMPF technique for diagnosing and predicting brain syndromes

NASA technology will now be available to the medical community to help in the diagnosis and prediction of syndromes that affect the brain, such as stroke, dementia, and traumatic brain injury.

21 Oct 2009

Research shows exon-skipping drug may prove effective for treating Duchenne muscular dystrophy

An exon skipping PPMO has demonstrated dramatic effects in the prevention and treatment of severely affected, dystrophin and utrophin-deficient mice, preventing severe deterioration of the treated animals and extending their lifespan.

21 Oct 2009

People living with diabetes to increase up to 435 million by 2030

The latest International Diabetes Federation (IDF) data reveals that over 285 million people worldwide now live with diabetes and this number will explode to 435 million by 2030. This staggering figure does not capture the toll the disease takes on the individual. Unlike other diseases, people with diabetes are responsible for 95% of their own care and many are doing so without the proper skills and knowledge to do so.

21 Oct 2009

Cook Medical launches new products for treating peripheral arterial disease

In a tour de force of new product development and introduction, Cook Medical is introducing six new products in parallel to provide better treatment options to the physicians treating the 27 million people worldwide* afflicted with some form of peripheral arterial disease (PAD) and other diseases of the circulatory system.

21 Oct 2009

Simcere and OSI Pharmaceuticals to market KDR/Kit inhibitor OSI-930 in China

Simcere Pharmaceutical Group ("Simcere" or the "Company"), a leading pharmaceutical company specializing in development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today announced an agreement with OSI Pharmaceuticals, Inc., to develop, manufacture, and market its KDR/Kit inhibitor OSI-930 in China.

21 Oct 2009

New research highlights brain's vulnerability to obesity

New research released today is affirming a long-held maxim: you are what you eat - and, more to the point, what you eat has a profound influence on the brain. The findings offer insight into the neurobiological factors behind the obesity epidemic in the United States and other developed countries.

20 Oct 2009

Positive data from BioSante Pharmaceuticals' LibiGel Phase III clinical development program

BioSante Pharmaceuticals, Inc., today announced positive safety data in its ongoing LibiGel Phase III clinical development program. For the first time, unblinded data have been reviewed by the independent DMC of the LibiGel Cardiovascular and Breast Cancer Safety Study. Based on this review of unblinded data, the DMC unanimously recommended continuation of the study as described in the study protocol, with no modifications.

20 Oct 2009

Stroke News and Research

Further Reading

Bristol-Myers Squibb reports strong sales and earnings growth for third quarter 2009

PacificGMP selected by ArmaGen Technologies to produce its proprietary protein for a Phase 1 clinical trial

Peripheral arterial disease linked to lifestyle changes

People in developing countries spend 90% of all medical expenditures for diabetes care

New research suggests physical therapy helps restore variety of functions after neurological injury

New study suggests potential treatment for blindsight patients

iPierian to participate in $3.7 million NIH grant awarded to The Johns Hopkins University

Shire to file a Biologics License Application for REPLAGAL with the FDA

Oxygen Biotherapeutics announces its expanded product development plan

APP Pharmaceuticals to launch Chlorothiazide Sodium for Injection

Comparative Effectiveness Research: One way to beat the competition

Class action lawsuit by patients who received high dosage of radiation during their CT brain perfusion scans

Findings suggest a new approach to the rehabilitation of stroke patients

MMPF technique for diagnosing and predicting brain syndromes

Research shows exon-skipping drug may prove effective for treating Duchenne muscular dystrophy

People living with diabetes to increase up to 435 million by 2030

Cook Medical launches new products for treating peripheral arterial disease

Simcere and OSI Pharmaceuticals to market KDR/Kit inhibitor OSI-930 in China

New research highlights brain's vulnerability to obesity

Positive data from BioSante Pharmaceuticals' LibiGel Phase III clinical development program

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News